TGF-β causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization

Li, Yixiang; Zhang, Baotong; Xiang, Lingwei; Xia, Siyuan; Kucuk, Omer; Deng, Xingming; Boise, Lawrence H.; Dong, Jin-Tang

doi:10.7150/thno.44567

Nanotheranostics

International Journal of Biological Sciences

International Journal of Medical Sciences

Journal of Cancer

open access Global reach, higher impact

Full Text | PDF

Theranostics 2020; 10(17):7656-7670. doi:10.7150/thno.44567 This issue Cite

Research Paper

TGF-β causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization

Yixiang Li^1,3, Baotong Zhang^1,3✉, Lingwei Xiang⁴, Siyuan Xia^1,3, Omer Kucuk^1,3, Xingming Deng^2,3, Lawrence H. Boise^1,3, Jin-Tang Dong^1,3✉

1. Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA.
2. Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA.
3. Winship Cancer Institute, Emory University, Atlanta, GA, 30322, USA.
4. ICF, Atlanta, GA, 30322, USA.

Citation:

Li Y, Zhang B, Xiang L, Xia S, Kucuk O, Deng X, Boise LH, Dong JT. TGF-β causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization. Theranostics 2020; 10(17):7656-7670. doi:10.7150/thno.44567. https://www.thno.org/v10p7656.htm

Other styles

Abstract

Prostate cancer is the second leading cause of cancer-related death in the United States. As a first line treatment for hormone-refractory prostate cancer, docetaxel (DTX) treatment leads to suboptimal effect since almost all patients eventually develop DTX resistance. In this study, we investigated whether and how TGF-β affects DTX resistance of prostate cancer.

Methods: Cytotoxicity of DTX in DU 145 and PC-3 cells was measured by CCK-8 and Matrigel colony formation assays. Resistance to DTX in DU 145 cells was examined in a xenograft tumorigenesis model. A luciferase reporter system was used to determine transcriptional activities. Gene expression was analyzed by RT-qPCR and Western blotting.

Results: We found that KLF5 is indispensable in TGF-β-induced DTX resistance. Moreover, KLF5 acetylation at lysine 369 mediates DTX resistance in vitro and in vivo. We showed that the TGF-β/acetylated KLF5 signaling axis activates Bcl-2 expression transcriptionally. Furthermore, DTX-induced Bcl-2 degradation depends on a proteasome pathway, and TGF-β inhibits DTX-induced Bcl-2 ubiquitination.

Conclusion: Our study demonstrated that the TGF-β-acetylated KLF5-Bcl-2 signaling axis mediates DTX resistance in prostate cancer and blockade of this pathway could provide clinical insights into chemoresistance of prostate cancer.

Keywords: KLF5 acetylation, TGF-β, Bcl-2 degradation, prostate cancer, docetaxel resistance

Citation styles

APA

Li, Y., Zhang, B., Xiang, L., Xia, S., Kucuk, O., Deng, X., Boise, L.H., Dong, J.T. (2020). TGF-β causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization. Theranostics, 10(17), 7656-7670. https://doi.org/10.7150/thno.44567.

ACS

Li, Y.; Zhang, B.; Xiang, L.; Xia, S.; Kucuk, O.; Deng, X.; Boise, L.H.; Dong, J.T. TGF-β causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization. Theranostics 2020, 10 (17), 7656-7670. DOI: 10.7150/thno.44567.

NLM

CSE

Li Y, Zhang B, Xiang L, Xia S, Kucuk O, Deng X, Boise LH, Dong JT. 2020. TGF-β causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization. Theranostics. 10(17):7656-7670.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.